What to know about the gBETA Medtech Fall cohort 2020:

  • Out of more than 200 companies that applied, five were chosen to participate in the (virtual) gBETA Medtech Fall cohort
    • CoraVie Medical
    • DrugViu
    • GRIP Molecular
    • HUED
    • Medical Ingenuities
  • The program (which kicked off on October 1) is a free, seven-week long accelerator designed to, “help startups gain early customer traction on their product or idea, and establish metrics that can make them competitive applicants for full-time, equity-based accelerators or seed investment.”
  • Participating companies will receive individualized coaching and access to gener8tor’s network of mentors, investors, and corporate partners
  • The seven weeks will end with the gBETA Pitch Series, “gener8tor is Grateful For…, on November 16 (RSVP here)

The Quote: Diane Rucker, Executive Director of gBETA Medtech sponsor University Enterprise Laboratories

“We’ve had an incredible response to the gBETA Medtech program and are excited to work with the five companies selected. With the pandemic, innovations in medtech, medical devices, health security and healthcare are more important than ever. UEL is proud to partner with gener8tor and with our partners to help support the growth of startups in medtech.”

Listen to our chat with Diane Rucker on The tech.mn Podcast.

 Read the full details (including more information about the participating companies) in the news release below. Release has been edited for length.

MINNEAPOLIS, MINNESOTA – Nationally-ranked startup accelerator gener8tor has announced the five companies participating in its gBETA Medtech Fall 2020 cohort. These startups are creating everything from blood pressure monitoring devices to platforms that diversify the patient-doctor connection.

gBETA Medtech is a free, seven-week accelerator that works with medical device, healthcare-related software, biotech and diagnostics startups for no fees and no equity. Each gBETA program is capped at five companies to ensure meaningful engagement with sponsors and other resources. Participants receive intensive, individualized coaching and access to gener8tor’s national network of mentors, customers, corporate partners and investors. The program is designed to help startups gain early customer traction on their product or idea, and establish metrics that can make them competitive applicants for full-time, equity-based accelerators or seed investment.

More than 200 startups applied to participate in the gBETA Medtech Fall 2020 cohort.

“We’ve had an incredible response to the gBETA Medtech program and are excited to work with the five companies selected,” said Diane Rucker, Executive Director of gBETA Medtech sponsor University Enterprise Laboratories. “With the pandemic, innovations in medtech, medical devices, health security and healthcare are more important than ever. UEL is proud to partner with gener8tor and with our partners to help support the growth of startups in medtech.”

gBETA Medtech’s Fall 2020 cohort kicked off on Oct. 1 with nine other gBETA programs across the country and will work with the gener8tor team over the course of seven weeks to meet mentors, gain customer traction and pitch to investors. Due to COVID-19, the Fall 2020 programs are all being held virtually.

These programs will culminate in gener8tor’s first gBETA Pitch Series, “gener8tor is Grateful For…,” which will highlight each of the fifty companies via Pitch Night events taking place each night the week before Thanksgiving. This series will be an opportunity to listen and learn more about the companies, network with the founders and other community members and celebrate everything we have to be thankful for during this time. To view information about the full Pitch Series, click here. Medtech’s cohort will be highlighted at the Pitch Night on Nov. 16th. For more information and to RSVP, click here.

“The pandemic has been a blessing for some healthcare startups and a curse for others, but one thing we know for sure is that the market is changing rapidly and founders need our support more than ever,” said gBETA Medtech Director Jackie Mejia. “The selected gBETA Medtech startups want to bring meaningful innovations to the healthcare industry and thanks to the support of our sponsors, we hope to provide the resources they need to succeed.”

gBETA Medtech is a program of University Enterprise Laboratories and gener8tor, and is sponsored by Boston Scientific with additional support from Mayo Clinic, University of Minnesota and Medical Alley Association. UEL and gener8tor also receive support through a cooperative agreement with the Biomedical Advanced Research and Development Authority – Division of Research, Innovation and Venture (BARDA DRIVe), a component of the US Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response. Startups interested in applying should contact gBETA Medtech Director Jackie Mejia at [email protected]. For more information, visit gbetamedtech.com.

gBETA Medtech Fall 2020 Cohort

CoraVie Medical’s end-to-end solution provides actionable data through its patent-pending subcutaneous blood pressure monitor. CoraVie Medical’s insights empower patients and clinicians to motivate behaviors to prevent the deadly progression of cardiovascular disease. Since launching in Q2 2020, CoraVie has entered into a collaboration agreement with a major university research center to complete proof of concept studies.

Co-Founder: Aimee Garza, CEO | [email protected] | www.coraviemedical.com

DrugViu’s platform makes medical research more inclusive and accessible by removing barriers and making it easy for all people living with autoimmune diseases to contribute to research that accelerates drug development. DrugViu has enrolled more than 5,000 autoimmune patients on its platform since March 2020 and is collaborating with two Fortune 50 biopharma companies.

Co-Founder: Kwaku Owusu, CEO | [email protected] | www.drugviu.com

GRIP Molecular’s single-use biosensor and mobile app provides consumers accurate and actionable medical diagnostic information in minutes and integrates with telehealth platforms. The patented solid-state electronic technology does not require special equipment or chemical reagents, making the product easy to use. GRIP’s first product simultaneously detects and characterizes the immune response to COVID-19, influenza and other common respiratory disease infections. Based upon the successful outcomes of prior research, development is underway and launch is anticipated in 2023.

Co-Founder: Edward Gillen, CEO | [email protected] | www.gripmolecular.com

HUED’s technology-enabled platform provides Black and Latino communities access to culturally-competent healthcare providers. These populations generally experience poor health outcomes due to fear, distrust, discomfort and lack of access to quality medical care, and there’s an increased need for culturally-competent healthcare providers who specifically understand their physical, mental, and cultural needs. HUED is a social impact organization with a mission to improve health outcomes for at least 50,000 Black and Latino patients by 2025.

Co-Founder: Kimberly Wilson, CEO | [email protected] | www.Huedco.com

Medical Ingenuities’ patent-protected PH Band eliminates complications and reduces workload after catheter procedures through the radial artery, like treatments commonly done after heart attacks. The PH Band acts as a “smart bandage” that regulates pressure on a point of access to prevent complications. Medical Ingenuities’ PH Band is pending 510(k) FDA clearance and has successfully completed 18 human cases at a major U.S. healthcare facility.

Co-Founder: Richard Corrigan, CEO | [email protected] | www.medicalingenuities.com